Filtered By:
Management: Funding
Therapy: Highly Active Antiretroviral Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study
Publication date: Available online 3 May 2018 Source:The Lancet HIV Author(s): Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft Background Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted daru...
Source: The Lancet HIV - May 15, 2018 Category: Infectious Diseases Source Type: research

Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study
Publication date: Available online 27 May 2015 Source:The Lancet HIV Author(s): Line D Rasmussen , Margaret T May , Gitte Kronborg , Carsten S Larsen , Court Pedersen , Jan Gerstoft , Niels Obel Background Whether the reported high risk of age-related diseases in HIV-infected people is caused by biological ageing or HIV-associated risk factors such as chronic immune activation and low-grade inflammation is unknown. We assessed time trends in age-standardised and relative risks of nine serious age-related diseases in a nationwide cohort study of HIV-infected individuals and population controls. Methods We identified all ...
Source: The Lancet HIV - May 28, 2015 Category: Infectious Diseases Source Type: research